Skip to content

Immix Biopharma, Inc. IMMX Operating Lease Liabilities

Operating Lease Liabilities at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
$72.63M-10.7%
Regenxbio logo
RegenxbioRGNX
$63.2M-12.1%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$6.96M+112%
Xencor logo
XencorXNCR
$62.6M-2.5%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Precigen logo
PrecigenPGEN
$3.66M-18.4%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s operating lease liabilities?
Immix Biopharma, Inc. (IMMX) reported operating lease liabilities of $912.34K in Q1 2026.
How has Immix Biopharma, Inc.'s operating lease liabilities changed year-over-year?
Immix Biopharma, Inc.'s operating lease liabilities decreased by 7.9% year-over-year, from $991.13K to $912.34K.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.